Last updated: October 3, 2026
Orapred ODT is a branded orally disintegrating formulation of prednisolone sodium phosphate. Its commercial value came from differentiated delivery, pediatric usability, and early formulation protection rather than from a novel active ingredient. The product’s market position weakened after generic prednisolone formulations and generic orally disintegrating tablets became available. Public company filings do not separately disclose Orapred ODT revenue, so its financial trajectory must be assessed through regulatory history, patent expiry, product ownership, generic entry, and the economics of the pediatric corticosteroid market.
What is Orapred ODT and how does it differ from prednisolone products?
Orapred ODT contains prednisolone sodium phosphate, a glucocorticoid used for inflammatory and allergic conditions. The product is an orally disintegrating tablet available historically in 10 mg, 15 mg, and 30 mg strengths. It is designed to dissolve in the mouth without requiring the patient to swallow a conventional tablet.
| Product characteristic |
Orapred ODT |
| Active ingredient |
Prednisolone sodium phosphate |
| Dosage form |
Orally disintegrating tablet |
| Historical strengths |
10 mg, 15 mg, 30 mg |
| Therapeutic class |
Systemic corticosteroid |
| Primary commercial differentiation |
Pediatric-friendly administration |
| FDA application |
NDA 21-870 |
| Initial FDA approval |
December 2003 |
| Prescription status |
Prescription drug |
| Primary market |
Pediatric and other patients with swallowing difficulty |
The active ingredient was well established before Orapred ODT approval. The commercial proposition was therefore based on formulation convenience, not new pharmacology. FDA labeling describes the product for corticosteroid-responsive disorders, including allergic, dermatologic, respiratory, rheumatic, hematologic, gastrointestinal, and other inflammatory conditions.[1]
When did Orapred ODT lose market exclusivity?
Orapred ODT did not receive meaningful long-term exclusivity based on a new chemical entity. Prednisolone was an established active ingredient, and the relevant protection centered on the dosage form and formulation.
The FDA approval date was December 11, 2003. Any product-specific regulatory exclusivity associated with new clinical investigations would have expired years ago. The principal commercial barrier was a formulation patent historically associated with orally disintegrating prednisolone tablets.
Orapred ODT exclusivity timeline
| Event |
Approximate timing |
Commercial effect |
| NDA 21-870 approved |
December 2003 |
Branded ODT launched |
| Formulation protection active |
Through the early 2020s |
Delayed direct ODT competition |
| Generic prednisolone liquids and conventional tablets |
Before and during Orapred commercialization |
Limited pricing power |
| Formulation patent expiration |
Approximately 2021-2022, depending on applicable term adjustment |
Opened the principal route to generic ODT competition |
| Current market position |
Post-exclusivity |
Mature, price-sensitive corticosteroid market |
The precise enforceable term depends on the patent record, terminal disclaimers, patent-term adjustment, and the product’s Orange Book listing at the relevant time. The commercial conclusion is clear: Orapred ODT no longer has a durable exclusivity position.
What patents protect Orapred ODT?
The principal historical patent associated with the product was U.S. Patent No. 6,872,716, assigned to Cima Labs, Inc. The patent covered orally disintegrating tablet technology relevant to Orapred ODT and was listed in connection with the product’s formulation protection.[2]
Historical Orapred ODT patent profile
| Patent |
Subject matter |
Historical relevance |
| U.S. Patent No. 6,872,716 |
Orally disintegrating tablet technology |
Principal formulation barrier associated with Orapred ODT |
| Product-specific regulatory exclusivity |
New formulation and clinical data, if applicable |
Expired |
| Active-ingredient protection |
Prednisolone sodium phosphate |
Not available; active ingredient was long established |
The patent estate was narrow compared with the patent portfolios of new chemical entities. It did not protect prednisolone itself, the broad therapeutic use of systemic corticosteroids, or every prednisolone dosage form. Generic companies could avoid infringement risk through conventional liquid, tablet, or alternative orally disintegrating formulations, subject to the claims in force at the time.
What is the Orange Book status of Orapred ODT?
Orapred ODT was listed in the FDA Orange Book as a prescription product associated with NDA 21-870. The Orange Book historically identified patent information for the product and provided the framework for abbreviated new drug application applicants to submit Paragraph IV certifications.[2]
The commercial significance of the Orange Book listing was limited by three factors:
- Prednisolone sodium phosphate was already widely used.
- The product’s defensible differentiation was concentrated in the ODT formulation.
- The market included multiple alternative dosage forms that did not need to replicate the ODT design.
Orange Book listing did not prevent generic approval of non-infringing prednisolone products. It primarily affected applicants seeking to market an equivalent ODT formulation during the listed patent term.
How many patents cover Orapred ODT?
The commercially relevant patent estate was small. One principal U.S. formulation patent is publicly associated with Orapred ODT, rather than a broad portfolio covering composition, method of use, manufacturing, and multiple delivery technologies.
This limited estate reduced lifecycle-management options. A product with a single formulation patent has fewer ways to delay generic entry than a product protected by separate patents covering:
- Active ingredient composition
- Extended-release technology
- Multiple dosage forms
- Device or delivery system
- Manufacturing process
- Specific patient populations
- Method-of-use claims
- Salt, polymorph, or crystal form
Orapred ODT did not have the structural characteristics of a high-barrier specialty product.
Which companies challenged Orapred ODT patents under Paragraph IV?
Publicly available product records indicate that generic competition developed around prednisolone sodium phosphate products and eventually included orally disintegrating tablet alternatives. The product’s historical patent position created an incentive for ANDA applicants to use Paragraph IV certifications or to wait for patent expiry.
A definitive company-by-company Paragraph IV chronology is not consistently presented in FDA product records. The absence of a detailed public chronology does not alter the market outcome: direct formulation protection expired, and the product entered a post-exclusivity commercial environment.
Generic launch scenarios
| Scenario |
Likely market effect |
| Generic ODT approval before patent expiry |
Potential patent litigation and delayed launch |
| Generic ODT approval after patent expiry |
Rapid price competition |
| Generic liquid or conventional tablet substitution |
Indirect erosion without exact dosage-form substitution |
| Authorized generic or licensed generic |
Lower branded share and reduced net pricing |
| Limited generic manufacturing capacity |
Temporary supply-driven price support |
The greatest risk was not a single first-filer event. It was cumulative substitution by lower-priced prednisolone products across dosage forms.
What formulations are protected by Orapred ODT patents?
The key protected feature was the orally disintegrating tablet formulation. Orapred ODT’s value depended on the interaction between rapid disintegration, acceptable taste, dose accuracy, stability, and pediatric administration.
The formulation’s commercial advantages included:
- No need to swallow a conventional tablet
- Less reliance on measuring a liquid dose
- Potentially easier administration for children
- Three historical dose strengths
- A differentiated product presentation in a generic corticosteroid category
These advantages did not create strong clinical differentiation. Physicians could prescribe prednisolone solution, conventional tablets, or other corticosteroid products when cost, availability, or patient preference outweighed the ODT benefit.
Manufacturing and intellectual-property barriers
The manufacturing barrier was moderate rather than high. A generic applicant needed to reproduce the dosage form’s performance, including:
- Tablet disintegration
- Content uniformity
- Chemical stability
- Taste and mouthfeel
- Mechanical strength
- Packaging protection
- Bioequivalence or applicable comparative testing
These requirements can raise development costs, but they do not normally create the same barrier as sterile injectables, complex biologics, depot products, or inhaled delivery systems. The product had no biosimilar risk because prednisolone sodium phosphate is a small-molecule drug, not a biologic.
What patent litigation affects Orapred ODT?
The principal legal risk centered on formulation patent infringement and the timing of generic entry. Orapred ODT did not present the litigation profile of a major biologic or blockbuster small-molecule product with numerous composition and method-of-use patents.
A complete public litigation assessment should distinguish among:
- Patent infringement actions following Paragraph IV notices
- ANDA litigation under the Hatch-Waxman Act
- Commercial disputes over supply or distribution
- Product-liability litigation
- Patent disputes concerning other prednisolone products
The commercial record supports a conclusion of limited long-term litigation value. Once the key formulation barrier expired, the product’s remaining defense was brand recognition, physician familiarity, distribution, and patient preference.
Did Orapred ODT have method-of-use patents?
The value of Orapred ODT was primarily formulation-based. Prednisolone has broad, established uses across inflammatory and allergic disorders, making broad method-of-use exclusivity difficult to sustain as a meaningful commercial barrier.
No durable method-of-use position appears to have protected the brand from generic substitution. A method-of-use patent covering a narrow population or dosing regimen would have had limited impact because physicians could often prescribe other prednisolone formulations for the same underlying condition.
Who marketed Orapred ODT and were there licensing deals?
Orapred ODT was historically marketed in the United States by Shire-related entities. Ownership and commercial responsibility changed over time as pharmaceutical companies reshaped portfolios and transferred rights to mature products.
Public filings have not consistently reported Orapred ODT as a separately material revenue line. That limits the ability to attribute product-level revenue to Shire or later commercial partners. Any distribution, licensing, or product-rights transaction involving the brand would have had greater significance for portfolio management than for the overall financial results of a large pharmaceutical company.
The product’s likely economic profile was a mature, niche prescription asset with:
- Low incremental clinical development requirements
- Modest manufacturing complexity
- Dependence on pediatric and specialty prescribing
- High exposure to generic substitution
- Limited ability to increase price after patent expiry
What is the FDA regulatory status of Orapred ODT?
Orapred ODT was approved under an NDA rather than an ANDA. Its approval established the branded product’s safety, efficacy, quality, and labeling for prednisolone sodium phosphate in the ODT dosage form.
The regulatory position after approval depended on:
- Continued manufacturing compliance
- Drug-supply availability
- Label maintenance
- Postmarketing reporting
- Orange Book status
- Availability of generic equivalents
FDA approval did not guarantee continued commercial availability. Mature prescription products can be discontinued, transferred, or replaced by generics even when the underlying NDA remains part of the historical regulatory record.
How strong is the Orapred ODT patent estate?
The patent estate was weak to moderate by branded pharmaceutical standards.
| Factor |
Assessment |
| Active ingredient protection |
Weak; prednisolone was established |
| Formulation protection |
Moderate during the patent term |
| Method-of-use protection |
Limited commercial significance |
| Manufacturing protection |
Moderate technical requirements, limited exclusionary scope |
| Regulatory exclusivity |
Expired |
| Biosimilar protection |
Not applicable |
| Post-expiry defense |
Weak |
| Generic substitution risk |
High |
The product’s strongest period was the interval in which the ODT formulation was commercially differentiated and direct generic ODT competition was restricted. Its weakest period began when the formulation patent expired and prescribers, pharmacies, and payers could substitute lower-cost products.
How did Orapred ODT revenue likely evolve?
No separately reported public revenue series establishes annual Orapred ODT sales. The financial trajectory is therefore best represented as a lifecycle model rather than as a verified dollar forecast.
Orapred ODT financial trajectory
| Lifecycle phase |
Revenue characteristics |
| Launch period |
Uptake driven by pediatric convenience and branded promotion |
| Protected growth |
Higher net price and limited direct ODT competition |
| Mature branded period |
Stable or declining volume; increasing payer scrutiny |
| Pre-expiry period |
Price pressure and generic anticipation |
| Post-expiry period |
Rapid net-price erosion and lower branded share |
| Late lifecycle |
Niche revenue dependent on availability and patient preference |
The product was unlikely to be a material driver of enterprise revenue for a diversified pharmaceutical company. Its economics were more consistent with a portfolio asset that could generate cash flow without large research investment before generic erosion.
How does Orapred ODT compare with competing prednisolone products?
| Product type |
Administration |
Cost position |
Patient convenience |
Generic risk |
| Orapred ODT |
Dissolves in mouth |
Highest when branded |
High for swallowing difficulty |
High after expiry |
| Prednisolone oral solution |
Liquid dosing |
Generally lower |
Useful for children, but requires measurement |
High |
| Conventional prednisolone tablet |
Swallowed tablet |
Low when generic |
Lower for young children |
High |
| Methylprednisolone products |
Tablet or other forms |
Variable |
Depends on dosage form |
High |
| Dexamethasone liquid or tablet |
Alternative corticosteroid |
Variable |
Depends on product |
High |
Orapred ODT’s competitive advantage was convenience. Its disadvantage was that convenience could be substituted by a liquid, compounded preparation, or conventional tablet. The product therefore had limited pricing power once payers and pharmacies prioritized generic alternatives.
What generic entry risks exist for Orapred ODT?
Generic entry risk is high and persistent. The principal risks are:
- Direct generic ODT competition after formulation-patent expiry.
- Substitution with generic prednisolone oral solution.
- Substitution with conventional prednisolone tablets.
- Pharmacy-level switching driven by formulary contracts.
- Supply disruptions that favor whichever manufacturer has inventory.
- Loss of branded shelf presence and physician attention.
The commercial impact depends on the number of approved manufacturers. One generic entrant can reduce price materially; multiple entrants typically accelerate erosion. The product’s low manufacturing complexity increases the probability of eventual competition, although shortages or limited manufacturing capacity can temporarily support pricing.
What is the geographic coverage of Orapred ODT?
The product’s principal commercial relevance was the U.S. prescription market, where the FDA NDA and Orange Book governed approval and substitution. Patent protection outside the United States would have depended on national filings, prosecution outcomes, supplementary protection rules, and local regulatory approvals.
The U.S. market had the clearest pathway to generic substitution because Hatch-Waxman ANDA procedures and Orange Book listings directly affected entry. International revenue, if any, would have depended on local brands, prednisolone formulations, reimbursement systems, and national patent status.
Key Takeaways
- Orapred ODT is a prednisolone sodium phosphate orally disintegrating tablet approved under NDA 21-870 in December 2003.
- Its commercial differentiation came from pediatric administration convenience, not a new active ingredient.
- U.S. Patent No. 6,872,716 was the principal historical formulation patent associated with the product.
- Regulatory exclusivity and meaningful formulation protection have expired.
- The product has no biosimilar exposure, but it faces substantial generic and dosage-form substitution risk.
- Public company filings do not separately disclose Orapred ODT revenue.
- The financial trajectory is consistent with a mature branded product: initial formulation-driven growth, followed by price and share erosion after generic entry.
- The remaining commercial value depends on availability, physician familiarity, patient preference, and limited ODT convenience.
- The patent estate is narrow and does not provide the layered protection seen in major innovative pharmaceutical products.
FAQs About Orapred ODT Patents, Generics, and Market Value
Is Orapred ODT still protected by a patent?
The principal historical formulation protection has expired or reached the end of its commercial term. Orapred ODT does not have durable active-ingredient protection.
Is Orapred ODT a biologic or biosimilar product?
No. Orapred ODT is a small-molecule corticosteroid product containing prednisolone sodium phosphate. Biosimilar competition does not apply.
Can a pharmacy substitute generic prednisolone for Orapred ODT?
Substitution depends on the specific generic product, state law, prescriber instructions, dosage form, and pharmacy practice. A liquid or conventional tablet may not be automatically substitutable for an orally disintegrating tablet in every jurisdiction.
Why did Orapred ODT command a premium over prednisolone liquid?
The premium reflected the orally disintegrating dosage form, pediatric convenience, dose presentation, and branded product economics. It was not based on a novel mechanism of action.
Is Orapred ODT revenue material to its historical manufacturer?
Public filings do not identify Orapred ODT as a separately material revenue contributor. Its economic importance was more consistent with a niche mature product than with a major enterprise revenue driver.
References
- U.S. Food and Drug Administration. (2003). Orapred ODT prescribing information, NDA 21-870.
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- United States Patent and Trademark Office. (2005). U.S. Patent No. 6,872,716: Orally disintegrating tablets.
- U.S. Food and Drug Administration. (1984). Drug Price Competition and Patent Term Restoration Act.
- U.S. Securities and Exchange Commission. (2004-2015). Public filings of Shire plc and related operating entities.
